Efficacy and safety of PG201 (Layla((R))) and celecoxib in the treatment of symptomatic knee osteoarthritis: a double-blinded, randomized, multi-center, active drug comparative, parallel-group, non-inferiority, phase III study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yoo, Wan-Hee | - |
dc.contributor.author | Yoo, Han-Gyul | - |
dc.contributor.author | Park, Sung-Hwan | - |
dc.contributor.author | Baek, Han-joo | - |
dc.contributor.author | Lee, Yun Jong | - |
dc.contributor.author | Shim, Seung Cheol | - |
dc.contributor.author | Kang, Seong Wook | - |
dc.contributor.author | Kim, Hyun Ah | - |
dc.contributor.author | Song, Jung Soo | - |
dc.contributor.author | Suh, Chang Hee | - |
dc.contributor.author | Choi, Sung Jae | - |
dc.contributor.author | Yoon, Bo Young | - |
dc.contributor.author | Tae, Dong Nyeon | - |
dc.contributor.author | Ko, Hyun Sook | - |
dc.contributor.author | Song, Yeong-Wook | - |
dc.date.accessioned | 2021-09-05T04:36:48Z | - |
dc.date.available | 2021-09-05T04:36:48Z | - |
dc.date.created | 2021-06-15 | - |
dc.date.issued | 2014-10 | - |
dc.identifier.issn | 0172-8172 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/97241 | - |
dc.description.abstract | The objectives of the study are to demonstrate the non-inferiority of PG201 (Layla(A (R))) 600 mg in comparison with celecoxib 200 mg for the treatment of symptomatic knee osteoarthritis (OA). In total, 309 patients were randomly assigned to receive either the test drug, PG201 600 mg (n = 154) or celecoxib 200 mg (n = 155). The primary efficacy variable was improvement in mean 100-mm pain VAS score from baseline to the final visit (week 8), and this value was compared between the 2 treatment groups. Secondary outcome variables included changes from baseline in the Western Ontario and McMaster Universities Arthritis Index (WOMAC) pain VAS score and subscale score, patient's global assessment of disease status quality of life (short form-36) and responder index at weeks 4 and 8. For safety assessment, adverse events were recorded at each clinical visit. At weeks 8, the 100-mm pain VAS scores were significantly decreased in patients receiving both PG201 600 mg (p < 0.0001) and celecoxib 200 mg (p < 0.0001) as compared to the baseline scores; however, no statistically significant differences in these values were noted between the groups (p = 0.312). These results met pre-specified criteria for non-inferiority for both the intent-to-treat and per-protocol populations. PG201 600 mg and celecoxib 200 mg were both well tolerated and no statistically significant differences in the tolerability profile between the groups. PG201 600 mg was as effective and safe as celecoxib 200 mg in the treatment of symptomatic knee OA and might be a useful new medication for the treatment of symptomatic knee OA. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | SPRINGER HEIDELBERG | - |
dc.subject | CHONDROITIN SULFATE | - |
dc.subject | STANDING-COMMITTEE | - |
dc.subject | INDUCED ARTHRITIS | - |
dc.subject | ETHANOL EXTRACT | - |
dc.subject | TASK-FORCE | - |
dc.subject | PLACEBO | - |
dc.subject | LUMIRACOXIB | - |
dc.subject | MANAGEMENT | - |
dc.subject | RECOMMENDATIONS | - |
dc.subject | GLUCOSAMINE | - |
dc.title | Efficacy and safety of PG201 (Layla((R))) and celecoxib in the treatment of symptomatic knee osteoarthritis: a double-blinded, randomized, multi-center, active drug comparative, parallel-group, non-inferiority, phase III study | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Choi, Sung Jae | - |
dc.identifier.doi | 10.1007/s00296-014-2964-8 | - |
dc.identifier.scopusid | 2-s2.0-84918802134 | - |
dc.identifier.wosid | 000342455600004 | - |
dc.identifier.bibliographicCitation | RHEUMATOLOGY INTERNATIONAL, v.34, no.10, pp.1369 - 1378 | - |
dc.relation.isPartOf | RHEUMATOLOGY INTERNATIONAL | - |
dc.citation.title | RHEUMATOLOGY INTERNATIONAL | - |
dc.citation.volume | 34 | - |
dc.citation.number | 10 | - |
dc.citation.startPage | 1369 | - |
dc.citation.endPage | 1378 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Rheumatology | - |
dc.relation.journalWebOfScienceCategory | Rheumatology | - |
dc.subject.keywordPlus | CHONDROITIN SULFATE | - |
dc.subject.keywordPlus | STANDING-COMMITTEE | - |
dc.subject.keywordPlus | INDUCED ARTHRITIS | - |
dc.subject.keywordPlus | ETHANOL EXTRACT | - |
dc.subject.keywordPlus | TASK-FORCE | - |
dc.subject.keywordPlus | PLACEBO | - |
dc.subject.keywordPlus | LUMIRACOXIB | - |
dc.subject.keywordPlus | MANAGEMENT | - |
dc.subject.keywordPlus | RECOMMENDATIONS | - |
dc.subject.keywordPlus | GLUCOSAMINE | - |
dc.subject.keywordAuthor | Knee osteoarthritis | - |
dc.subject.keywordAuthor | PG201 | - |
dc.subject.keywordAuthor | Celecoxib | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.